Treatment of Lymphangiomas in Children: An Update of Picibanil (OK‐432) Sclerotherapy
- 1 October 1999
- journal article
- clinical trial
- Published by Wiley in Otolaryngology -- Head and Neck Surgery
- Vol. 121 (4) , 381-387
- https://doi.org/10.1016/s0194-5998(99)70225-1
Abstract
Picibanil (OK-432) is a sclerosing agent derived from a low-virulence strain of Streptococcus pyogenes that induces regression of macrocystic lymphangiomas. This report describes a prospective, non...Keywords
This publication has 13 references indexed in Scilit:
- OK-432 Therapy for LymphangiomasJAMA Otolaryngology–Head & Neck Surgery, 1996
- OK-432 therapy for lymphangioma in children: Why and how does it work?Journal of Pediatric Surgery, 1996
- Lymphatic Malformations of the Head and Neck: A Proposal for StagingJAMA Otolaryngology–Head & Neck Surgery, 1995
- OK-432 therapy in 64 patients with lymphangiomaJournal of Pediatric Surgery, 1994
- Cystic Lymphangioma and Plunging Ranula Treated by OK-432 Therapy: A Report of Two CasesActa Oto-Laryngologica, 1994
- OK-432 therapy for unresectable lymphangiomas in childrenJournal of Pediatric Surgery, 1991
- Cystic hygroma‐lymphangioma: A rare and still unclear entityThe Laryngoscope, 1989
- Intracystic injection of OK-432: A new sclerosing therapy for cystic hygroma in childrenBritish Journal of Surgery, 1987
- Induction of interferon-γ in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenesCellular Immunology, 1982
- Cystic hygroma in children: A report of 126 casesJournal of Pediatric Surgery, 1974